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Prostate cancer cells produce high (microgram to
milligram/milliliter) levels of the serine protease Pros-
tate-Specific Antigen (PSA). PSA is enzymatically
active in the extracellular fluid surrounding prostate
cancers but is found at 1,000- to 10,000-fold lower
concentrations in the circulation, where it is inacti-
vated due to binding to abundant serum protease
inhibitors. The exclusive presence of high levels of
active PSA within prostate cancer sites makes PSA
an attractive candidate for targeted imaging and
therapeutics. A synthetic approach based on a pep-
tide substrate identified first peptide aldehyde and
then boronic acid inhibitors of PSA. The best of these
had the sequence Cbz-Ser-Ser-Lys-Leu-(boro)Leu,
with a Ki for PSA of 65 nM. The inhibitor had a 60-
fold higher Ki for chymotrypsin. A validated model
of PSA’s catalytic site confirmed the critical interac-
tions between the inhibitor and residues within the
PSA enzyme.
INTRODUCTION
Prostate cancers selectively produce a number of unique pros-
tate tissue differentiation markers. In particular, prostate cancer
cells, like normal prostate epithelial cells, produce large amounts
of Prostate-Specific Antigen (PSA) (Watt et al., 1986; Lilja et al.,
2000). PSA is aptly named, in that it is specifically and exclusively
produced by normal and malignant prostate epithelial cells and
is not produced in any significant amounts by other normal tissue
in the human male. On this basis, PSA is used extensively as
a biomarker to screen for prostate cancer, to detect recurrence
after local therapies, and to follow response to systemic thera-
pies for metastatic disease (Watt et al., 1986; Lilja et al., 2000;
Williams et al., 2007b; Denmeade and Isaacs, 2004).
However, accumulating evidence suggests that PSA may be
more than just a biomarker and may play a role in the pathobiol-
ogy of prostate cancer (Williams et al., 2007b). Functionally, PSA
is a 33 kDa serine protease belonging to the human kallikrein
gene family. In the freshly ejaculated semen, PSA maintainsChemistry & Biology 15the semen in a semiliquid state through its ability to cleave the
major gel-forming proteins semenogelin I (SgI) and semenogelin
II (SgII), which are synthesized and secreted by the seminal ves-
icles (Malm et al., 2000; Lilja, 1985; Lilja et al., 1989). In normal
prostate tissue, high concentrations of PSA are stored in the
prostatic ductal network (Williams et al., 2007b). A very small
quantity of enzymatically active PSA leaks out of the prostatic
ductal network and forms complexes with the serum protease
inhibitor a-1-antichymotrypsin (ACT) to generate the low nano-
gram/milliliter levels that can be measured in the circulation
(Williams et al., 2007b).
In contrast, the disruption of normal tissue architecture in the
prostate or distal sites by prostate cancer cells results in the
leakage of increased amounts of PSA into the tissue interstitium
and then into the circulation (Williams et al., 2007b). Enzymati-
cally active PSA in the interstitium can subsequently degrade
extracellular matrix proteins such as fibronectin and laminin.
PSA can also release growth factors bound within the matrix
structure. Previous in vitro studies have documented PSA’s abil-
ity to cleave insulin-like growth factor binding protein 3 (IGFBP3)
(Cohen et al., 1992), the small latent form of TGFb2 (Dallas
et al., 2005), and parathyroid-hormone-related protein (PTHrP)
(Iwamura et al., 1996). More recent in vitro studies demonstrated
that the PTHrP peptide fragment generated by PSA hydrolysis
may function as an osteoblastic factor through activation of the
endothelin A receptor (Schluter et al., 2001; Chirgwin et al.,
2004).
Although these studies are compelling, it remains to be deter-
mined if these in vitro findings with purified proteins necessarily
provide insights into whether PSA plays any relevant role in pros-
tate cancer biology in vivo. The delineation of a functional role for
PSA in the growth and progression of prostate cancer in vivo
would be greatly facilitated by the availability of a small-molecule
PSA inhibitor. To achieve this goal, in this study we describe the
synthesis and characterization of potent and selective low-mo-
lecular weight, peptidyl-based PSA inhibitors. The template for
the design of the inhibitor was a previously described PSA pep-
tide substrate, identified from a map of cleavage sites within SgI
and SgII (Denmeade et al., 1997). This substrate has been used
to generate PSA-activated prodrugs and protoxins (Denmeade
et al., 2003; Williams et al., 2007a). In the present study, we uti-
lized an iterative approach toward developing peptidyl boronic
acid-based PSA inhibitors with inhibition constant (Ki) values in, 665–674, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 665
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Peptidyl Boronic Acid Inhibitors of PSAthe low nanomolar range. A lead boronic acid-based inhibitor
discovered by this method was found to be highly specific for
PSA versus chymotrypsin and other serine and nonserine prote-
ases. The inhibitor was further characterized for its ability to
inhibit PSA degradation of PSA substrates and for its effects
on PSA production and growth of PSA-producing xenografts
in vivo.
RESULTS
Peptide Aldehyde Screening
PSA exhibits chymotrypsin-like activity, preferentially cleaving
after hydrophobic residues such as leucine and tyrosine. This ac-
tivity is due in part to the presence of a serine in the S-1 specific-
ity pocket of the catalytic site. As a starting point for the synthesis
of peptidyl boronic acid-based inhibitors of PSA, we chose to
evaluate peptides based on a PSA substrate with the sequence
Ser-Ser-Lys-Leu-Gln (SSKLQ) (Denmeade et al., 1997). Although
previous studies in our laboratory demonstrated PSA’s relatively
unique ability to cleave peptide bonds after the amino acid glu-
tamine (Denmeade et al., 1997), we opted to substitute the
hydrophobic amino acids leucine and norleucine in the P1 posi-
tion due to the complex nature of the glutamine side chain.
Glutamine peptide aldehydes are severely limited in their utility
since they exist mainly in the cyclic hemiaminal form (Webber
et al., 1998), and the synthesis of a glutamine boronic acid is
not feasible. Leucine and norleucine were selected because
they were previously shown to be preferred P1 position substit-
uents for PSA, and the synthesis of boronic acid derivatives
of these two amino acids is known and can be accomplished
in relatively high yield (Matteson et al., 1984, 1986).
Initially, we characterized inhibitors containing either the alde-
hyde Leu-H (i.e., SSKLL) or Nle-H (i.e., SSKLNle) in the P1 posi-
tion (Table 1). From these studies, the calculated inhibition con-
stants (Ki) were determined for Z-SSKLL-H and Z-SSKLNle-H to
be 6.51 mM and 11.24 mM, respectively, for PSA. To confirm that
the inhibition was not due merely to the occupancy of the cata-
lytic site by the peptide, Z-SSKLL-OH and Z-SSKLNle-OH, as
well as the corresponding amides of these peptides, were syn-
thesized and tested (Table 1). Likewise, the peptide alcohol
Z-SSKLL-CH2OH did not inhibit PSA. Peptide versions of the
PSA substrate used in the activity assay, without an AMC group
at the C terminus, were also tested to rule out the possibility of
product inhibition occurring during the duration of the assay.
For all peptides lacking the C-terminal aldehyde functional group
or aldehydesmade from the D-isomer of both leucine and norleu-
cine, the Ki values all were greater than 1000 mM. These studies
document that the substitution of aldehyde-functionalized Leu or
Nle in the P1 position of the PSA peptide substrate produces
peptide aldehydes with Ki values in the low micromolar range.
Previously, a positional scanning approach was used to inves-
tigate amino acids preferred by PSA in each position (i.e., P1–P6)
of a series of random peptides (Debela et al., 2006). This study
documented that PSA has a preference for leucine in the P2 po-
sition (Debela et al., 2006). To evaluate whether peptides lacking
a P2 leucine or other hydrophobic amino acids could still inhibit
PSA, the aldehydes Z-SSKL-H and Z-SSKNle-H and the dipep-
tides Z-KL-H, Z-KNle-H, Z-QL-H, and Z-QNle-H (Table 1) were
generated. All of the peptide aldehydes lacking a P2 hydropho-666 Chemistry & Biology 15, 665–674, July 21, 2008 ª2008 Elseviebic amino acid had Ki values for PSA of > 1000 mM. In contrast,
Z-LLL-H (MG132), a known 26S proteasome inhibitor, was syn-
thesized and tested. Unlike the other inactive shorter peptide
aldehydes, this peptide with P2 and P3 leucine residues had a
Ki for PSA of 13.2 mM. Other amino acids were also evaluated
in the P2 position of full-length sequences and included
Z-SSKYL-H (Ki = 13.09 mM), Z-SSKQL-H (Ki = 21.8 mM),
Z-SSKIL-H (Ki = 37.4 mM), Z-SSKKL-H (Ki = 57.8 mM), Z-SSKVL-
H (Ki = 70.7 mM), and Z-SSKAL-H (Ki = 173.4 mM), as well as the
dipeptide Z-YL-H (Ki = 541.4 mM) (Table 1). These results further
document the preference for Leu in the P2 position.
In subsequent studies, we evaluated the contribution of amino
acids in the P4-P5 position of the peptide (Table 1). The aldehyde
lacking the P5 serine residue (Z-SKLL-H) had a 6.5-fold higher
Ki than the full-length sequence containing two serines. Peptide
aldehydes lacking both P4 and P5 serine residues maintained
Table 1. Ki Values for PSA Inhibition by Leucine and Norleucine
Aldehydes and Peptides
Compound Ki (mM)
Leucine Aldehydes
1 Z-SSKLL-H 6.51 ± 0.25
2 Z-SSKYL-H 13.09 ± 0.91
3 Z-SSKQL-H 21.79 ± 0.51
4 Z-SSKIL-H 37.43 ± 2.43
5 Z-SSKKL-H 57.85 ± 1.14
6 Z-SSKVL-H 70.71 ± 1.77
7 Z-SSKAL-H 173.4 ± 6.12
8 Z-SKLL-H 42.43 ± 2.13
9 Z-KLL-H 171.3 ± 6.88
10 Z-YL-H 514.4 ± 11.47
11 Z-KL-H >1000
12 Z-QL-H >1000
13 Z-SSKL-H >1000
14 Z-SSKLL-H >1000
15 Z-SSLKL-H >500
16 Z-LKSSL >1000
17 Z-LLL-H (MG132) 13.23 ± 0.86
Norleucine Aldehydes
18 Z-SSKLNle-H 11.24 ± 0.26
19 Z_KLNle-H 414.1 ± 22.49
20 Z-KNle-H >1000
21 Z-QNle-H >1000
22 Z-SSKNle-H >1000
23 Z-SSKLNle-H >1000
Peptides
24 Z-SSKLL-OH >1000
25 Z-SSKLL-NH2 >1000
26 Z-SSKLL-CH2OH >1000
27 Z-SSKLNle-OH >1000
28 Z-SSKLNle-NH2 >1000
29 Mu-SRKSQQY-OH >1000
30 Mu-SRKSQQY-NH2 >1000
31 Ac-HSSKLQL-OH >1000r Ltd All rights reserved
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Peptidyl Boronic Acid Inhibitors of PSAthe ability to inhibit PSA, but to a much lesser degree than the
full-length sequences. Z-KLL-H and Z-KLNle-H had Ki values
of 171.3 mM and 414.1 mM, respectively, which were 25- to 35-
fold higher than the corresponding full-length inhibitors.
Peptidyl Boronic Acids
Peptide aldehydes have little utility in complex biological
systems due to their inherent reactivity with numerous nucleo-
philes and cysteine proteases (Dufour et al., 1995). Although
both aldehydes and boronic acids act as potent inhibitors of
serine proteases by mimicking the tetrahedral transition state
of peptide-bond hydrolysis (Thompson, 1973), boronic acids are
more effective inhibitors (Walker and Lynas, 2001). Since our
goal was to generate a PSA inhibitor that could be used in vivo,
a strategy using peptidyl boronic acids was pursued by using the
sequence preferences discovered in the primary peptide alde-
hyde screen.
In contrast to the results with the peptide aldehydes, the
shorter dipeptidyl boronic acids Z-Q(boro)L and Z-K(boro)L
now had measurable Ki values of 265 mM and 353 mM, respec-
tively (Table 2). Even inhibitors lacking a P2 leucine exhibited
amarked inhibitory improvement, with Ki values of Z-SSK(boro)L
and Z-SSKL(boro)Nle now ranging from 18.49 mM to 34.21 mM.
These values were both at least 50-fold lower than the Ki values
for the corresponding aldehydes, which were both greater than
1000 mM (Table 2).
Significant improvement in the Ki was also observed for the P2
leucine-containing peptidyl boronic acids. The shortest P2 leu-
cine inhibitors, Z-KL(boro)L and Z-KL(boro)Nle, both had low-mi-
cromolar Ki values of 5.98 mMand 23.57 mM, respectively. The Ki
of Z-SSKL(boro)Nle was found to be submicromolar at 398 nM.
Table 2. Ki Values for PSA Inhibition by Leucine and Norleucine
Boronic Acid Peptides
Peptidyl Boronic Acid Ki (mM)
32 Z-Q(boro)L 265.15 ± 18.39
33 Z-K(boro)L 353.5 ± 23.68
34 Z-SSK(boro)L 18.49 ± 1.48
35 Z-SSK(Boro)Nle 34.21 ± 0.83
36 Z-KL(boro)L 5.98 ± 0.24
37 Z-KL(boro)Nle 23.57 ± 0.47
38 Z-SSKL(boro)Nle 0.398 ± 0.020
39 Z-SSKL(boro)L 0.065 ± 0.005
Derivatives with D-Isomer Amino Acids
40 Z-SSKL(boro)L 0.149 ± 0.009
41 Z-SSKL(boro)L 21.48 ± 2.28
42 Z-SSKL(boro)L 28.67 ± 1.32
43 Z-SSKL(boro)L 75.76 ± 5.21
44 Z-SSKL(boro)L 32.21 ± 1.73
45 Z-SSKL(boro)L 227.27 ± 11.61
46 Z-SSKL(boro)L 439.94 ± 19.04
Lysine Derivatives
47 Z-SSL(boro)L 3.86 ± 0.29
48 Z-SSK(Ac)L(boro)L 0.294 ± 0.026
D-Amino acids are underlined.Chemistry & Biology 1However, the best PSA inhibitor that was developed by using this
screening method was Z-SSKL(boro)L, which was found to have
a Ki of 65 nM (Figure 1).
Z-SSKL(boro)L Sequence Modification
To further delineate the PSA pharmacophore and the relative
importance of each amino acid residue to the inhibitory function
of the Z-SSKL(boro)L inhibitor, D-amino acids were incorporated
into each position of the sequence, except for the P1 boronic
acid position, (Table 2). In positions P2–P4 of the peptide (i.e.,
41–46), incorporation of one or multiple D-amino acids markedly
increased the Ki. In contrast, placing a D-serine in the P5 position
of the inhibitor as in 40 did not completely abrogate function and
only increased the Ki 2-fold. These results further documented
the relative importance of the P4 serine in comparison to the
serine in the P5 position.
In additional studies, the contribution of the lysine in the P3
position of Z-SSKL(boro)L was addressed (Table 2). The pres-
ence of this lysine makes the inhibitor a potential substrate for
degradation by trypsin-like proteases, thus possibly decreasing
the half-life of the molecule in vivo. Z-SSL(boro)L, which lacks
lysine in P3, still possessed some ability to inhibit PSA, with a
Ki of 3.86 mM. Interestingly, the omission of lysine altogether pro-
duced a less dramatic effect than replacement with D-lysine, as
evidenced by the8-fold higher Ki for Z-SSKL(boro)L compared
to Z-SSL(boro)L. Substituting lysine with neutral N-3-acetyl-ly-
sine resulted in an inhibitor that was 4.5-fold less potent, but
still produced an inhibitor with a Ki below 300 nM.
Overall Binding Mode of Peptide Inhibitor
Previously, we described and validated a molecular model of the
catalytic site for PSA (Singh et al., 2008). In order to gain insights
into preferred binding interactions thatmight help in the design of
additional PSA inhibitors, we used this model to study binding
of the Z-SSKL(boro)L into the PSA catalytic site. Using this
model, the overall binding orientation of peptide inhibitor
(S5S4K3L2(boro)L1) as produced by GOLD docking calculations
is shown in Figure 1A. All residues except the P1 residue (L1)
are bound in an extended configuration, which is consistent
with the canonical view of how peptide substrates and inhibitors
bind at the catalytic pocket of serine proteases (Figure 2A). The
backbone atoms of P3-P1 residues are in the correct orientation
to forma short, antiparallel b sheetwith residues 204–206 of PSA.
This b sheet conformation is interrupted at the P1 residue, which
adopts the values of dihedral angles in the right-handed a-helical
(aR) region of the Ramachandran plot. The boronic moiety at the
C terminus of the P1 residue is bound in a configuration mimick-
ing the tetrahedral transition state during substrate hydrolysis
(Figure 2B). The deprotonated oxygen of the boronic moiety
makes a hydrogen bondwith the protonated nitrogen (N32) of the
catalytic triad His41 residue, whereas the hydroxyl group of the
boronic moiety is oriented toward GLY 187 in the oxyanion
hole. This orientation of the boronic moiety and the rest of the
inhibitor is in agreement with the high-resolution crystal structure
of serine proteases such as a-lytic protease crystallized with a
transition state analog containing boronic acid (Bone et al.,
1987).
Subsequently, we analyzed the side chain orientation of select
amino acids residues in the P1-P5 position and determined the5, 665–674, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 667
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Peptidyl Boronic Acid Inhibitors of PSAFigure 1. Experimental Methods by Which to Calculate Ki Values
(A) Example of progress curves for the inhibition of PSA by Z-SSKL(boro)L over a range of concentrations.
(B) Linear plot of no/ni 1 versus [I] for Z-SSKL(boro)L at indicated concentrations. The reciprocal of the slope of the line equals the apparent inhibition constant,
Ki(app). Ki is then calculated by using the equation Ki = Ki(app)/(1 + [(S)/Km]). All assays were performed in triplicate; the average value at each time point was plotted.nature of their energetic interactions with nearby protease resi-
dues (Figure 2B). The P1 residue (boroL1) binds at the specificity
pocket lined by polar residues with the partial hydrophobic side
chains such as S217, T184, and Y219. The presence of these
residues imparts a hydrophobic character to the sides of the
specificity pocket and, at the same time, a polar character to
the bottom of the pocket. This allows for optimum binding of me-
dium-sized hydrophobic residues such as leucine, but not of the
large-sized residues such as tryptophan. These hydrogen bonds
buried deep within the protease core are likely to be strong since
the energetic penalty for an unsatisfied hydrogen bond buried in
the protein core is very high. Our docking studies also suggested
that although the unnatural amino acid norleucine binds at the P1
pocket in the correct conformation, the binding is energetically
less favorable than the leucine residue. This finding is consistent
with the observed Ki value of 398 nM for Z-SSKL(boro)Nle, which
is 5-fold higher than that of Z-SSKL(boro)L.
The model predicts that the P2 residue (L2) side chain is
docked against the face of the imidazole ring of the catalytic
His41 residue (Figure 2B). On the opposite side, the g-branched
side chain of leucine is in close contact with the hydrophobic
Trp205 residue. Additionally, polar residues such as Ser93 and
Tyr77 also line the farthest end of the P2 pocket, creating an
electronegative potential and providing polar characteristics to
the P2 pocket. Consistent with the mixed polar-hydrophobic
characteristics of the P2 pocket, in silico positional scanning
revealed that the P2 pocket is permissive in allowing residues
ranging from polar ones such as tyrosine and hydrophobic resi-
dues such as leucine and norleucine. Exceptions are isoleucine
(negative GOLD score), which sterically clashes with the P2
pocket residues. This finding correlates with the observed differ-
ences in the series of aldehyde inhibitors with different P2
residues, with only an 2-fold higher Ki for Z-SSKYL-H but an
6-fold higher Ki for Z-SSKIL-H compared to Z-SSKLL-H.
The P3 residue (K3) acts as a lid to the specificity pocket and
docks at a location just above theP1-binding site in the specificity
pocket. The aliphatic side chain of K3 is positioned in the vicinity
of the hydrophobic phenylalanine group of the Phe141 residue
and also in close contact with the methylene group of the
Ser186 side chain (Figure 2B). More importantly, the free amine
group of K3 is within 4.5 A˚ of the carboxyl moiety of the Glu208668 Chemistry & Biology 15, 665–674, July 21, 2008 ª2008 Elsevieside chain. Whereas the orientation of the Glu208 side chain is
not ideal, there is a strong possibility for salt bridge formation
with the 3-amine of K3. The presence of an acidic residue at
position 208 is not common in the chymotrypsin family of serine
proteases. The inhibitory potencies of modifications at the P3
position supported these insights. Modifications of the lysine
residue that would potentially disrupt salt bridge formation with
Glu208, such as acetylation of the lysine residue or elimination
of the K3 residue, increase the Ki 5-fold and 60-fold, respectively.
The P4 pocket is located in the lower groove area and ismainly
formed by His164, Pro165, Gln166, and Trp205 residues.
The P4-binding pocket is bound by the kallikrein loop from
above, but loop residues are not involved in any important ener-
getic interactions. The Gln166 side chain is ideally placed to form
a hydrogen bond with the hydroxyl of P4 serine (Figure 2B). The
presence of Gln166 at this position is unique for PSA and not
common in other serine proteases from the kallikrein family.
The importance of this interaction with S4 is demonstrated by
a marked increase in Ki for inhibitors lacking S4, with a 90-fold
increase in Ki for Z-KL(boro)L and a 59-fold increase in Ki for
Z-KL(boro)Nle. In addition, substitution of the D-isomer at the
S4 position produces a 330-fold increase in the measured Ki.
Finally, the S5 side chain is docked in the lower groove area, but
it is exposed to the solvent, and there are no specific interactions
with the protease residue. This suggests that P5 and additional
N-terminal amino acid residues should not provide a significant
contribution toward the overall binding affinity of the inhibitor
molecule. This assertion is supported by our experimental find-
ing that substitution of a D-isomer at S5 produced only a 2-fold
increase in Ki (i.e., from 65 nM to 149 nM).
Specificity of the Z-SSKL(boro)L PSA Inhibitor
Having determined Z-SSKL(boro)L to be our best candidate
inhibitor (Ki = 65 nM), we next determined its specificity for
PSA relative to other proteases. The effect of Z-SSKL(boro)L
as an inhibitor on the canonical serine proteases chymotrypsin
and trypsin was investigated. Z-SSKL(boro)L was also tested
with the serine proteases dipeptidyl peptidase 4 (DPP-4) and
elastase and the nonserine proteases cathepsin B and cathepsin
D, (Table 3). Although chymotrypsin is capable of cleaving after
leucine residues, the Ki for inhibiting chymotrypsin was 60-foldr Ltd All rights reserved
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Peptidyl Boronic Acid Inhibitors of PSAFigure 2. Binding Mode of Inhibitor Z-
S5S4K3L2(boro)L1 in the Catalytic Pocket
of PSA
(A) Surface representation of a structural model of
PSA and the overall orientation of the inhibitor in
the catalytic site. Catalytic triad residues (HIS41,
ASP96, and SER189) are shown in yellow. Also
depicted are the major topological features of
PSA structure, i.e., S-1 pocket, upper groove,
lower groove, arginine patch, and valley region.
(B) Interactions of the Z-S5S4K3L2(boro)L1 inhibitor
with the key residues in the catalytic pocket.
Catalytic triad residues are shown in yellow, the
protease residues are shown in magenta, and
the backbone of 204–206 residues is shown in
green. Dotted lines represent hydrogen bonds,
and the dotted circle pinpoints the exact location
of the boronic acid moiety.higher than for PSA. As was expected, the Z-SSKL(boro)L inhib-
itor did not inhibit trypsin or DPP-4 to any degree. Modest inhibi-
tion of elastase, another serine protease that prefers hydropho-
bic P1 residues, was observed. However, the inhibitor was still
22 timesmore selective for PSA over elastase. In an earlier study,
we had demonstrated that the SSKLQ-AMC substrate could be
hydrolyzed by the cysteine protease cathepsin B and the aspar-
tyl protease cathepsin D (Denmeade et al., 1997). In contrast, no
inhibition of either cathepsin B or cathepsin D by Z-SSKL(boro)L
was observed over a range of concentrations, consistent with
the fact that boronic acids alone are not effective inhibitors
of cysteine or aspartyl proteases (Martichonok and Jones,
1997) . However, the lack of inhibition of these proteases by
Z-SSKL(boro)L, even at high concentrations, demonstrates
that the peptide sequence itself, although potentially a substrate
for these proteases, is not capable of inhibiting the proteases in
a noncovalent fashion.
Z-SSKL(boro)L Prevents the Degradation of Known PSA
Substrates
In vitro PSA has been shown to cleave IGFBP3, resulting in the
release of the prostatic mitogen IGF-1 (Cohen et al., 1992).
In the bone, IGF-1 is known to be a strong promoter of osteo-
blastic activity (Chirgwin et al., 2004). Recombinant IGFBP3
was digested with PSA in the presence and absence of the inhib-
itor Z-SSKL(boro)L (Figure 3A). In the absence of the inhibitor,
PSA completely degraded IGFBP3, as seen by the disappear-
Table 3. Selectivity for PSA Inhibition by Z-SSKL(boro)L versus
a Panel of Proteases
Protease Ki (mM) Selectivity
a
PSA 0.065 1
Chymotrypsin 3.9 60
Trypsin >100 >1500
DPPIV >100 >1500
Cathepsin B NDb -
Cathepsin D ND -
Elastase 1.39 22
aSelectivity relative to PSA inhibition.
bND, no detectable inhibition up to 500 mM.Chemistry & Biology 15ance of the IGFBP3 band on the western blot. In contrast, the
addition of the PSA inhibitor to the digest mixture protected
IGFBP3 from degradation by PSA.
Previously, it was demonstrated in vitro that PTHrP 1–141, an
endocrine hormone that stimulates bone resorption, can be hy-
drolyzed efficiently by PSA to release a 22 amino acid fragment
(Iwamura et al., 1996). To study the effect an inhibitor could have
on the PSA-mediated degradation of PTHrP, a 34 amino acid
PTHrP peptide containg the PSA cleavage site was incubated
with purified PSA (Figure 3B). After 1 hr, mass spectroscopic
analysis demonstrated that PSA had completely digested the
PTHrP peptide 1–34, cleaving the peptide after a Phe residue
(RFFYLHH). The resulting 22 amino acid fragment with an m/z
of 2781.40 could be further cleaved, yielding a peptide with an
m/z of 2193.06. PSA cleavage of the PTHrP peptide was com-
pletely inhibited in the presence of the inhibitor Z-SSKL(boro)L.
Z-SSKL(boro)L Decreases the Clonal Survival
of PSA-Producing Prostate Cancer Cells In Vitro
Previous in vitro studies have suggested a role for PSA in pro-
moting the growth and invasion of human prostate cancer cells.
To evaluate the effect of Z-SSKL(boro)L inhibition of PSA on
growth, a panel of PSA-positive (LNCaP, LAPC-4, CWR22R,
C4-2B) and negative (DU145, PC3) human prostate cancer cell
lines was treated with the inhibitor at concentrations up to 15-
fold higher than the Ki for PSA inhibition. In this study, cells
were allowed to attach to the tissue culture plastic for 24 hr prior
to exposure to the inhibitor. Under these conditions, the inhibitor
at 100 nM showed a marginal effect and at 1 mM inhibited the
growth of all cell lines, independent of PSA production, by
10%–25% (Figure 3C).
Besides the PSA substrates IGFBP3 and PTHrP described
above, PSA has also been shown to be able to cleave extracel-
lular matrix proteins such as fibronectin (Lilja et al., 2000) and
release matrix-associated growth factors such as TGFb (Dallas
et al., 2005). These results suggest that PSA may possibly play
a role in the process of extracellular matrix deposition required
for cells to grow in vivo and to become established on plastic
culture dishes in vitro. Therefore, in the next study, we assessed
the ability of the Z-SSKL(boro)L inhibitor to inhibit attachment
and subsequent clonal survival of newly plated individual cells.
In this assay, the clonal survival of PSA-positive LNCaP human, 665–674, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 669
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Peptidyl Boronic Acid Inhibitors of PSAFigure 3. Z-SSKL(boro)L Inhibits the Degradation of PSA Substrates and the Clonal Survival of PSA-Producing Prostate Cancer Cells
(A) Western blot of IGFBP3 incubated with PSA ± the inhibitor Z-SSKL(boro)L.
(B) Digest of PTHrP peptide 1–34 with PSA ± the inhibitor Z-SSKL(boro)L. The digest was monitored by MALDI-TOF mass spectrometry.
(C) The effect of the inhibitor on the growth of indicated prostate cancer cell lines.
(D) The effect of the inhibitor on clonal survival of PSA-producing LNCaP cells and non-PSA-producing TSU human bladder cancer cells.prostate cancer cells plated in the presence Z-SSKL(boro)L
was inhibited 75% at 100 nM and 85% at 1 mM compared to
vehicle-treated control (Figure 3D). In contrast, the clonal survival
of PSA-negative TSU human bladder cancer cells was inhibited
by only 25% under these same conditions.
In Vivo Evaluation of the Lead PSA Inhibitor
On the basis of the in vitro results, the SSKL(boro)L inhibitor was
subsequently evaluated in vivo for efficacy against CWR22R-H,
a PSA-producing human prostate cancer xenograft. For in vivo
studies, a more water-soluble form of the inhibitor was gener-
ated by substituting amorpholinocarbonyl (Mu) protecting group
at the N terminus. This substitution did not affect the Ki for PSA
inhibition (data not shown).
In initial toxicologic studies, it was determined that repeat in-
travenous doses of 33 mg/kg of the Mu-SSKL(boro)L inhibitor
were well tolerated and had no significant effects on mouse
body weight. A dose of 100 mg/kg produced transient weight
loss, whereas a dose of 300 mg/kg was lethal to one-third of the
mice. Therefore, the 33 mg/kg dose was used for subsequent in
vivo studies. As control animals received equimolar doses of the
inactive D-amino acid isomer 46 according to the same dosing
schedule. The growth of tumors treated with these two peptidyl
boronic acids was compared to vehicle-treated control
(Figure 4A). The Mu-SSKL(boro)L inhibitor produced a slight
decrease in tumor volume that only achieved statistical signifi-
cance at day 6 prior to starting the second cycle of inhibitor
(Figure 4A). The D-amino acid analog had no effect on tumor
growth compared to control (data not shown).670 Chemistry & Biology 15, 665–674, July 21, 2008 ª2008 ElsevierHowever, whereas the inhibitor had minimal effect on growth,
it had a relatively profound effect on measured PSA levels (Fig-
ure 4B). Free PSA levels were 35% lower in the PSA inhibi-
tor-treated animals, whereas total PSA (free PSA + complexed
PSA) levels were 30% lower (Figure 4B). No significant differ-
ence in PSA levels was observed for the inactive D-amino acid
isomer-treated animals. Over the 10 day period between PSA
measurements, the free PSA levels/gram of tumor increased
by 70% in the control animals, but only by 13% in the inhibi-
tor-treated group (Figure 4C). Similarly, total PSA levels/gram
of tumor increased 3.4-fold in the control-treated animals, but
only 1.85-fold in the Mu-SSKL(boro)L-treated animals, whereas
the D-amino acid analog had no significant effect on change in
PSA compared to the control group.
DISCUSSION
The goal of this study was to develop a potent and selective
peptide-based PSA inhibitor that could be used to help elucidate
the role of PSA in the pathobiology of prostate cancer. These in-
hibitors potentially could be used for the development of pros-
tate cancer-targeted therapies and imaging agents. Although
an anti-PSA monoclonal antibody-based approach could also
be envisioned, such a targeted antibody would have to be devel-
oped that could bind selectively to the high levels of enzymati-
cally active PSA that are exclusively present in the extracellular
peritumoral fluid within prostate cancer sites. This is an impor-
tant caveat in the design of a PSA inhibitor given thatmultiple iso-
forms of PSA, all of which are enzymatically inactive, are presentLtd All rights reserved
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ous PSA-Producing CWR22R-H Xenografts
(A) Relative change in tumor volume of tumors in mice (n = 10/group) treated
intravenously with either vehicle control or PSA inhibitor at a dose of 33mg/kg/
dose3 6 total doses. The days of dosing are indicated by arrows. The asterisk
indicates p < 0.05 via a Student’s t test.
(B) Serum levels of free and total PSA/gram of tumor measured 24 hr after the
last dose of inhibitors. (p < 0.05 for both free PSA and total PSA levels in PSA
inhibitor-treated animals versus vehicle controls).
(C) Fold change in free and total PSA/gram of tumor in mice treated with vehi-
cle control or D-amino acid inhibitor or Mu-SSKL(boro)L at 33 mg/kg/dose 3
6 doses. Fold increase is equal to (1  [ratio of PSA/gram of tumor measuredChemistry & Biology 1in the circulation of patients with prostate cancer. Therefore, an
advantage of this peptide-based inhibitor approach is that it
selectively targets the proteolytic activity of PSA present only
in the extracellular fluid of prostate cancers. Peptides have
a number of additional distinct advantages over antibody-based
approaches (Bander, 2006). These include small size, easy prep-
aration, toleration of the harsh conditions of chemical modifica-
tions or radiolabeling, higher penetration into tumors, low toxic-
ity, and potential high affinity and specificity for the protease
catalytic site. On this basis, a number of peptide-based ap-
proaches for imaging and therapy are currently in use clinically
(Okarvi, 2004; Sato et al., 2006; Kane et al., 2003), including bor-
tezomib, a peptidyl boronic acid-based proteasome inhibitor
approved for the treatment of multiple myeloma.
For in vivo studies, both the potency and selectivity of the PSA
inhibitor are of paramount importance in the selection of a ‘‘lead’’
inhibitor candidate. In these studies, we determined that the
Z-SSKL(boro)L inhibitor had a Ki of 65 nM, making this com-
pound the most potent PSA inhibitor described to date. In addi-
tion, our overall design strategy produced inhibitors that were
relatively selective for PSA inhibition. From the outset, the mech-
anisms underlying boronic acid-based protease inhibition limited
the inhibitory potential only to the serine/threonine protease
class. The inclusion of a hydrophobic amino acid in the P1 posi-
tion adds further specificity by preventing nonspecific inhibition
of trypsin and trypsin-like serine proteases (Martichonok and
Jones, 1997).
To evaluate the unique interactions between the amino acids
in the Z-SSKL(boro)L inhibitor and residues within the PSA cata-
lytic site., we used a molecular model of the PSA catalytic site
that was developed based on the crystal structure of porcine
kallikrein and HK1, two proteins with relatively high sequence
homology to PSA. In particular, HK1 has it kallikrein loop in the
correct orientation and provides an ideal template on which to
build a PSA homology model. This model was previously vali-
dated by using a series of published b-lactam compounds (Singh
et al., 2008; Adlington et al., 2001). Subsequent to these studies,
the crystal structure of PSA bound to an anti-PSA antibody was
published (Me´nez et al., 2008). However, we have assessed the
goodness of the fit between our homology model and the crystal
structure and found that the root means square difference (rmsd)
value for all atoms is 2.2 A˚, indicating that the homology model is
indeed structurally very similar to the published crystal structure.
Furthermore, structurally important residues in the catalytic
pocket have the same conformation in both structures, further
justifying the high confidence and validity of our homology
model.
PSA does share some substrate preferences with chymotryp-
sin, such as hydrophobic residues like leucine in the P1 position.
Thus, the selectivity of the PSA inhibitor for inhibition of PSA ver-
sus chymotrypsin appeared to be due to unique binding interac-
tions between the side chains of the additional amino acids in the
Z-SSKL(boro)L inhibitor and residues within the PSA catalytic
site. These modeling studies demonstrated a potential for salt
24 hr after the sixth dose of inhibitor compared to PSA/gram of tumor
measured 24 hr prior to the first dose of inhibitor]). The asterisk indicates
p < 0.05 via a Student’s t test.5, 665–674, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 671
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Peptidyl Boronic Acid Inhibitors of PSAbridge formation between the P3 Lys andGlu208 and a hydrogen
bond between the hydroxyl of P4 serine and the side chain
Gln166 in the PSA protein. Chymotrypsin lacks such an acidic
residue at position 208, and the presence of Gln166 at this posi-
tion is unique for PSA and not common in other serine proteases.
These observations may in part explain the observed 60-fold dif-
ference in Ki values for PSA and chymotrypsin even though
leucine was placed in the P1 position.
In vivo, the lead PSA inhibitor was marginally active against
a subcutaneous PSA-producing human prostate cancer xeno-
graft. These results suggest that the PSA inhibitor may not be
adequately inhibiting PSA production within the xenograft. Alter-
natively, PSA activity may play no functional role in the growth of
this subcutaneously implanted xenograft. Existing data support
a role for PSA in the generation of osteoblastic bonemetastases.
The ability of our inhibitor to block the degradation of PTHrP and
cleavage of IGFBP3 suggests that our inhibitor may produce
a more significant biologic response in a more relevant model.
This question is being addressed in ongoing studies in our labo-
ratory by using intratibial prostate tumor implantation as a model
for osteoblastic metastases. Regardless of the model, future
in vivo mechanistic studies with the PSA inhibitor will require fur-
ther optimization of the in vivo stability and pharmacokinetics
of the peptidyl-based inhibitor.
Although the inhibitor did not significantly inhibit the growth of
the PSA-producing xenografts, the effect of the inhibitor on se-
rumPSA levels provides evidence of a biological effect. Although
tumor sizes of the control- and PSA inhibitor-treated groups
were relatively equal at the time of PSA measurement, the inhib-
itor-treated animals had significantly lower levels of both free and
total PSA compared to both vehicle-treated controls and animals
treated with the D-amino acid isomer, which was a very poor
inhibitor of PSA in vitro. These results suggest that the PSA inhib-
itor may be altering the clearance of PSA from the circulation.
Enzymatically active PSA that is released into the circulation
forms a complex with either a-1-antichymotrypsin (ACT) or
a-2-macroglobulin (A2M) (Williams et al., 2007b). PSA rapidly
forms an irreversible complex with A2M that is rapidly cleared
by the liver (i.e., t1/2 = minutes). The magnitude of the PSA-
A2M complex formation inmenwith prostate cancer is unknown,
as this PSA form cannot be measured via ELISA-based assays.
In contrast, the kinetics of PSA-ACT complex formation is slow,
and the half-life of the complex is hours to days. PSA-ACT can be
measured via ELISA and is the major form of PSA in the circula-
tion. Our working hypothesis is that the PSA inhibitor may alter
PSA binding to ACT, thereby increasing irreversible entrapment
by A2M in the serum. The end result of this increased clearance
is an overall decrease inmeasurable PSA levels in the circulation.
Further studies are ongoing in support of this hypothesis.
SIGNIFICANCE
Large amounts of enzymatically active PSA are continuously
produced by all stages of prostate cancer, including cancers
in men with advanced, high-grade, hormone-refractory can-
cer. This observation, coupled with growing experimental
evidence, suggests that PSA plays an important role in the
pathobiology of prostate cancer. These observations also
support the development of PSA-selective inhibitors as use-672 Chemistry & Biology 15, 665–674, July 21, 2008 ª2008 Elsevierful tools to further validate PSA as a therapeutic target. In
addition, the exclusive production of active PSA only in the
tumor interstitiumwith subsequent rapid inhibition by serum
protease inhibitors emphasizes that PSA is truly a ‘‘prostate-
specific’’ protein that has yet to be exploited therapeutically
or as an imaging target. The significance of this work, there-
fore, is that we describe a rational and iterative approach to
develop potent and highly selective PSA inhibitors based on
previously known PSA peptide substrate. As we describe,
the PSA peptide inhibitor discovered by this approach is a
useful tool that can be used to evaluate the role of PSA in the
growth, invasion, and metastasis of prostate cancer. The
modeling studies provide insights as to additional modifica-
tions that could be made to optimize the peptide for in vivo
applications. The chemical flexibility of the peptide platform
allows for easy modification of the peptide. The modeling
studies and the recently published crystal structure docu-
ment that bulky moieties such as cytotoxin and imaging
agents could be added to the amino terminus of the peptide
inhibitor without interfering with its ability to inhibit PSA.
Future studies with these inhibitors will be directed toward
developing a fuller understanding of the role of PSA in pros-
tate cancer development and progression and the genera-
tion of PSA-targeted therapies and imaging agents.
EXPERIMENTAL PROCEDURES
Peptide Aldehyde and Boronic Acid Synthesis
For synthetic details, see the Supplemental Data (available online).
PSA Assays and Inhibition Kinetics
The assay for PSA activity was performed as previously described (Denmeade
et al., 1997). The PSA concentration per assay was 2.5 mg/ml (2 nM active PSA)
with a PSA substrate concentration of 300 mM. Substrate hydrolysis ± inhibitor
over a range of concentrations was monitored by measuring fluorescence
change secondary to AMC release by using a Fluoroskan 96-well fluorometric
plate reader (excitation, 355 nm; emission, 460 nm) connected to a Macintosh
computer with Deltasoft 3 software. Complete hydrolysis of the substrate was
maintained below 5% to ensure that the substrate concentration was essen-
tially constant. Ki values were determined by using the method of progress
curves as described earlier (Salvesen and Nagase, 2001). Data were plotted
as no/ni  1 versus [I], where vo is the rate of substrate hydrolysis in the ab-
sence of inhibitor, vi is the rate of substrate hydrolysis in the presence of inhib-
itor, and [I] is the concentration of PSA inhibitor. The plots of no/ni 1 versus [I]
were linear, with the reciprocal of the slope of the line equal to the apparent in-
hibition constant, Ki(app). The inhibition constant, Ki, was then calculated by us-
ing the equation Ki = Ki(app)/(1 + [(S)/Km]). The Km value of the PSA substrate,
Mu-SRKSQQY-AMC (California Peptides), was 140 mM, as determined by
kinetic analysis with Sigma Plot software.
Homology Model of PSA
The three-dimensional structural model of PSA was developed based on the
crystal structure of porcine kallikrein (PDB code: 2PKA) and the human tissue
kallikrein HK1 (PDB code: 1SPJ). The details of themodel construction and the
software package used for model building are described in a previous study
that reported the application of this model for gaining mechanistic insights
into the inhibition of PSA by the b-lactam class of molecules (Singh et al.,
2008). This homology model of PSA has its kallikrein loop in a semi-open con-
figuration, which results in a catalytic site accessible to both inhibitors and
substrates. This model is an improvement over previous models of PSA that
were developed by using a single template and a de novo kallikrein loop design
(Coombs et al., 1998; Villoutreix et al., 1994), which is less accurate than the
loop design based on actual crystal structure templates, such as the human
tissue kallikrein structure (1SPJ) used in our study.Ltd All rights reserved
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For our docking studies, the GOLD v3.0 program developed by CCDC (Cam-
bridge, UK) was used to dock peptide inhibitors into the catalytic site of PSA by
using previously described methods (Singh et al., 2008). The catalytic site was
defined by a spherical space with 25 A˚ radius centered on the catalytic serine
residue (Ser189). For every peptide inhibitor, 20 independent runs (GA = 20)
were performed, resulting in 20 different docking poses ranked by their
GOLD Score. For every independent run, the number of operations performed
(Nop) was 100,000. To eliminate personal bias, the top-scoring pose for every
peptide inhibitor was used as the most probable binding conformation. To
guide the docking process, a single distant constraint was used, which re-
strained the boron atom of the C-terminal boronic acid moiety within 1.5–3.5 A˚
from the side chain oxygen atom of catalytic serine residue (Ser189) by using
a spring constant of 5 kcal/mol.
Ligand preparation for the docking studies was done by using theMOE soft-
ware package (CCG,Montreal). All peptidic inhibitors were built in an extended
conformation by using the Builder module within the software package, and
partial charges were assigned by using the CHARM22 force field. Special at-
tention was paid while building the boronic moiety at the end of the C terminus
of the peptide inhibitors since this part of the molecule forms transition state-
like tetrahedral interactions with the catalytic serine side chain and the 3 nitro-
gen (N32) of the catalytic histidine residue (His41).
PSA Inhibitor Specificity Studies
The inhibitory constants for each protease tested were determined by using
the method mentioned previously. For determining the inhibitor specificity
for cathepsin D, a Cathepsin D Assay Kit (Sigma) was used according to the
manufacturer’s specifications with the substrate Mca-GKPILFFRLK-Dnp.
The conditions for other protease assays were: DPP-4 (5 nM) + 400 mM
AP-AFC in a buffer of 100 mM Tris and 100 mM NaCl (pH 7.8); cathepsin B
(7 nM) + 50 mM Z-RR-AMC in a buffer of 50 mM acetate, 2.5 mM DTT, and
2.5 mM EDTA (pH. 5.5); elastase (1.5 nM) + 20 mM suc-AAPV-AMC; trypsin
(5 nM)+ 200mMBz-R-AMC; chymotrypsin (2 nM)+ 25mMsuc-AAF-AMC. These
three proteases were assayed by using 50 mM Tris and 0.1 M NaCl (pH 7.8).
PTHrP Peptide Digest with PSA
PTHrP peptide 1–34 (1.0 mM) was digested with 2 nM PSA in PSA assay
buffer ± inhibitor (1.5 mM) at 37C for 1 hr. Aliquots of the digests were taken
at different time points, desalted by using P10-C18 ZipTips (Millipore), and
spotted (0.5 ml) on a MALDI-TOF plate. Spots were mixed with 0.5 ml matrix
consisting of 10 mg/ml recrystalized cyano-4-hydroxy cinnamic acid in 50%
ethanol/water. Mass spectra were acquired on an Applied Biosystems Voy-
ager DE-STR MALDI-TOF mass spectrometer at the Johns Hopkins School
of Medicine Mass Spectrometry and Proteomics Facility. The mass spectrom-
eter was calibrated by using the ProteoMass Peptide MALDI Calbration Kit
(Sigma). All spectra were acquired in positive ion mode.
IGFBP3 Digest with PSA
IGFBP3 (500 ng) was incubated with purified PSA (50 ng) ± 500 nM inhibitor in
PSA assay buffer at 37C. Aliquots were taken at different time points, and the
digests were quenched by freezing in liquid nitrogen. Digests were resolved on
Bio-Rad ReadyGels, 4%–15%Tris-HCl. IGFBP3was visualized by using a pu-
rified goat polyclonal antibody raised against the C terminus of IGFBP3 (Santa
Cruz Biotechnology).
Cytotoxicity Assays
Assays were performed by using the PSA-producing cell line LNCaP (human
prostate cancer), and non-PSA producing TSU (human bladder cancer) was
purchased from ATCC and maintained in RPMI-1640 supplemented with 10%
fetal bovine serum at 37C, 5% CO2, humidified air as previously described
(Christensson et al., 1990). After cells were exposed to agent for 72 hr, MTT
cell proliferation assays were performed according to the manufacturer’s
instruction, and clonal survival assayswere performed as previously described
(Christensson et al., 1990).
In Vivo Studies
In vivo studies were performed by using the PSA-producing human prostate
cancer xenograft CWR22R-H. This model is passaged as a xenograft andChemistry & Biology 15grows in a castrated host. Derivation and characterization of this xenograft
has been previously described (Chandran et al., 2007). Animals bearing subcu-
taneous CWR22R-H xenografts (n = 10 per group) received intravenous injec-
tion of test compounds in sterile normal saline. Tumors were measured by
using vernier calipers, and tumor volume was determined by using the formula
L 3 W 3 H 3 0.5236. Body weight was measured twice weekly. All animal
studies were performed according to procedures and protocols approved
by the Johns Hopkins University Animal Care and Use Committee.
SUPPLEMENTAL DATA
Supplemental Data include the synthetic protocols and characterization data
for all of the peptide aldehyde and boronic acid compounds described in
this report and are available at http://www.chembiol.com/cgi/content/full/15/
7/665/DC1/.
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